Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application Covering Extracorporeal Treatment of COVID-19 and Other Medical Maladies
Jackson Center, PA, March 18, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Method for Treating and Curing Covid-19 Infection.” The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously. William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, “We believe this technology has sufficient merit to seek patent protection ...
Halberd Corporation Starts VITA-SHIELD-MAX(TM) Immunity Boosting Nutraceutical Production
Jackson Center, PA, March 16, 2021 – Halberd Corporation (OTC PINK:HALB) has contracted with a major nutraceutical manufacturer to produce its initial production lot of Halberd’s VITA-SHIELD-MAXTM Immune Booster. Halberd’s scientists designed this proprietary combination of vitamins and minerals to help the body increase its natural immunity and promote general health. Dr. Patricio Reyes, Halberd Corporation’s Chief Technical Officer, indicated, “Halberd’s formulation was not arrived at lightly. After much research and discussions with medical professionals ...
Halberd Corporation Files VITA-SHIELD-MAX(TM) Trademark For Immunity Boosting Nutraceutical
Jackson Center, PA, March 11, 2021 – Halberd Corporation (OTC PINK:HALB) has filed for trademark protection for the name VITA-SHIELD-MAXTM for its proprietary blend of over-the-counter nutraceuticals designed to boost the body’s immunity and generally enhance health. William A. Hartman, Chairman, President & CEO of Halberd Corp., stated, “We are pleased to be able to complete this next step in producing and marketing our proprietary blend of ingredients to help boost immunity and general health. ...
Halberd Corporation’s CEO Interviewed on “The Stock Day Podcast” – Focus on Halberd’s New 20x Affinity Neutralizing SARS-COV-2 Antibody
Jackson Center, PA, March 9, 2021 – Halberd Corporation’s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on The Stock Day Podcast, hosted by Everett Jolly. In the interview, Mr. Hartman reviewed the company’s progress in developing SARS-CoV-2 spike protein antibodies and how they can be combined with other Halberd technologies in fighting Covid-19 and other diseases. Hartman commented on Halberd’s newly created antibody, which has been shown to have a ...
Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater
Jackson Center, PA, March 2, 2021 – Halberd Corp. (OTC PINK:HALB) has recently produced a proprietary monoclonal antibody that has at least 20 times greater neutralizing affinity than their original antibody against the SARS-COV 2 Spike protein. Dr. Reyes, Halberd’s Chief Technical Officer, indicated, “Our latest results indicate increased specificity of our second antibody, which can be used as a stand-alone or in combination with other antibodies for the overall optimum management of COVID-19. Based ...
Halberd Collaborates With GreenBioAZ, Inc. For the Development of Its Patent Pending Radio Frequency Technology to Eliminate Disease Pathogens
Jackson Center, PA, February 16, 2021 – Halberd Corp. (OTC PINK:HALB) has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease pathogens. The methodology entails treating bodily fluids with an Antibody-Metallic Moiety Conjugate (AMMC) which targets a specific pathogen such as SARS-CoV-2 during extracorporeally exposing bodily fluids to a specific Radio Frequency wavelength. This will permit the established frequency of the electromagnetic wave being ...